tradingkey.logo
tradingkey.logo
Search

Odyssey Therapeutics Ord Shs (Proposed)

ODTX
Add to Watchlist
19.140USD
-0.960-4.78%
Close 11-13 16:00(ET)
919.87MMarket Cap
LossP/E TTM

About Odyssey Therapeutics Ord Shs (Proposed) Company

Odyssey Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It is developing medicines that are designed to precisely target disease pathology with an initial emphasis on the innate immune system. Its advanced programs include OD-001, an oral small-molecule scaffolding inhibitor of receptor-interacting protein kinase 2, or RIPK2, and OD-002, an oral small-molecule inhibitor of solute carrier family 15 member 4, or SLC15A4. These programs have the potential to yield treatments for inflammatory and autoimmune diseases. In addition to its advanced programs, it has a portfolio of preclinical programs that include a regulatory T cell, or Treg, -specific tumor necrosis factor receptor 2, or TNFR2, agonist, a bispecific antagonist of thymic stromal lymphopoietin, or TSLP, and interleukin-33, or IL-33, and an interleukin-1 receptor-associated kinase 4, or IRAK4, scaffolding inhibitor. It also has an interferon regulatory factor 5, or IRF5, inhibitor in preclinical development.

Odyssey Therapeutics Ord Shs (Proposed) Profile

Ticker SymbolODTX
Company nameOdyssey Therapeutics Inc
IPO dateMay 08, 2026
CEOGlick (Gary D)
Number of employees151
Security typeOrdinary Share
Fiscal year-endMay 08
Address51 Sleeper Street
CityBOSTON
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code02210
Phone16178659628
Websitehttps://odysseytx.com
Ticker SymbolODTX
IPO dateMay 08, 2026
CEOGlick (Gary D)

Company Executives of Odyssey Therapeutics Ord Shs (Proposed)

Name
Name/Position
Position
Shareholding
Change
Dr. Jeffrey M. (Jeff) Leiden, M.D., Ph.D.
Dr. Jeffrey M. (Jeff) Leiden, M.D., Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
265.20K
--
Mr. Ian F. Smith, CPA
Mr. Ian F. Smith, CPA
Independent Director
Independent Director
246.10K
--
Mr. Jason Haas
Mr. Jason Haas
Chief Financial Officer
Chief Financial Officer
61.91K
--
Dr. Shelley Chu, M.D., Ph.D.
Dr. Shelley Chu, M.D., Ph.D.
Independent Director
Independent Director
11.11K
--
Mr. Timothy P. (Tim) Walbert
Mr. Timothy P. (Tim) Walbert
Independent Director
Independent Director
--
--
Ms. Nia Tatsis, Ph.D.
Ms. Nia Tatsis, Ph.D.
Independent Director
Independent Director
--
--
Ms. Ksenija Ksenija
Ms. Ksenija Ksenija
Independent Director
Independent Director
--
--
Dr. Valerie Odegard, Ph.D.
Dr. Valerie Odegard, Ph.D.
Independent Director
Independent Director
--
--
Dr. Carolyn Ng, Ph.D.
Dr. Carolyn Ng, Ph.D.
Independent Director
Independent Director
--
--
Mr. Nan Li
Mr. Nan Li
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Jeffrey M. (Jeff) Leiden, M.D., Ph.D.
Dr. Jeffrey M. (Jeff) Leiden, M.D., Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
265.20K
--
Mr. Ian F. Smith, CPA
Mr. Ian F. Smith, CPA
Independent Director
Independent Director
246.10K
--
Mr. Jason Haas
Mr. Jason Haas
Chief Financial Officer
Chief Financial Officer
61.91K
--
Dr. Shelley Chu, M.D., Ph.D.
Dr. Shelley Chu, M.D., Ph.D.
Independent Director
Independent Director
11.11K
--
Mr. Timothy P. (Tim) Walbert
Mr. Timothy P. (Tim) Walbert
Independent Director
Independent Director
--
--
Ms. Nia Tatsis, Ph.D.
Ms. Nia Tatsis, Ph.D.
Independent Director
Independent Director
--
--

FAQs

Who are the top five shareholders of Odyssey Therapeutics Ord Shs (Proposed)?

The top five shareholders of Odyssey Therapeutics Ord Shs (Proposed) are: Dr. Jeffrey M. (Jeff) Leiden, M.D., Ph.D.
tradingkey.logo
Risk Warning: Our Website and Mobile App provides only general information on certain investment products. Finsights does not provide, and the provision of such information must not be construed as Finsights providing, financial advice or recommendation for any investment product.
Investment products are subject to significant investment risks, including the possible loss of the principal amount invested and may not be suitable for everyone. Past performance of investment products is not indicative of their future performance.
Finsights may allow third party advertisers or affiliates to place or deliver advertisements on our Website or Mobile App or any part thereof and may be compensated by them based on your interaction with the advertisements.
© Copyright: FINSIGHTS MEDIA PTE. LTD. All Rights Reserved.